ALLMedicine™ Hypophosphatemia Center

Jan 20th, 2022 - Phosphaturic mesenchymal tumor (PMT) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, and bone calcification disorders. Complete surgical resection of the tumor is believed to be the most effective trea...

Jan 19th, 2022 - The aim of this study was to determine if hypophosphatemia is more common in patients with severe alcohol-induced acute pancreatitis (AAP). This is a retrospective, single institution, cohort study that analyzed 147 patients admitted to the hospit...

Jan 18th, 2022 - Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in PHEX results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults. FGF23 is a hormone ...

Jan 15th, 2022 - Osteomalacia is caused by an increase in the number of osteoids owing to mineralization failure. There are various causes of osteomalacia, such as hypophosphatemia due to excess production of fibroblast growth factor 23, vitamin D deficiency, insu...

Jan 14th, 2022 - We present the case of a 32-year-old man with a history of hypophosphatemia and multiple bone fractures, being evaluated at our center for a potential mesenchymal tumor. 68Ga-DOTATATE PET/CT revealed a highly 68Ga-DOTATATE-avid lesion in the ethmo...

Jan 18th, 2022 - Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in PHEX results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults. FGF23 is a hormone ...

Jan 11th, 2022 - Methodology This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The objectives of this XLH Registry is to collect natural history data of XLH to character...

Dec 17th, 2021 - X-linked hypophosphatemia is a skeletal dysplasia. The mineralized tissue complications of XLH have been the focus of investigative studies seeking to understand its pathogenesis, as well as studies directed at new therapies. However, in addition ...

Aug 9th, 2021 - BUR-CL207 is a multicenter, open-label, non-randomized Phase 1/2 study in pediatric patients with XLH initiating treatment with burosumab at <12 months of age. The study includes a total treatment period of up to 48 weeks across 3 cohorts. Subject...

May 5th, 2021 - X-linked hypophosphatemia (XLH) is a vitamin D-resistant familial rickets resulting from a mutation of the PHEX gene. One of the major clinical disorders is dental pulp necrosis, which results in "spontaneous" dental abscesses not related to cario...

Nov 2nd, 2021 - NEW YORK (Reuters Health) - Adults with X-linked hypophosphatemia (XLH) have high rates of musculoskeletal problems that start as early as age 20 years and gradually accumulate over the years, a new analysis confirms. XLH is a rare inherited disor...

Nov 1st, 2021 - The FGFR inhibitor infigratinib (Truseltiq) demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or re...

Oct 6th, 2021 - Brian Rini, MD The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma (mRCC), according to two recently published articles ...

Sep 10th, 2021 - A single dose of ciltacabtagene autoleucel (cilta-cel) continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma, according to updated data from the phase 1...

Aug 31st, 2021 - Key clinical point: Adding entinostat to e xemestane does not improve survival in aromatase inhibitor (AI)-resistant advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Major finding: Th.